X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (347) 347
Patent (9) 9
Publication (9) 9
Conference Proceeding (5) 5
Book Chapter (4) 4
Dissertation (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
oncology (123) 123
humans (116) 116
index medicus (97) 97
female (85) 85
male (83) 83
middle aged (80) 80
aged (78) 78
chemotherapy (78) 78
cancer (64) 64
adult (61) 61
colorectal cancer (57) 57
gastric cancer (49) 49
metastasis (46) 46
stomach cancer (46) 46
antineoplastic combined chemotherapy protocols - therapeutic use (43) 43
care and treatment (38) 38
patients (37) 37
stomach neoplasms - drug therapy (35) 35
medicine & public health (34) 34
cancer research (33) 33
fluorouracil (33) 33
survival (33) 33
treatment outcome (33) 33
analysis (30) 30
cancer therapies (29) 29
oxaliplatin (29) 29
research (28) 28
colorectal neoplasms - drug therapy (27) 27
neoplasm staging (27) 27
surgical oncology (27) 27
colorectal neoplasms - pathology (26) 26
clinical trials (25) 25
stomach neoplasms - pathology (25) 25
therapy (25) 25
trial (24) 24
aged, 80 and over (23) 23
cisplatin (23) 23
gastroenterology (23) 23
japan (23) 23
mutation (23) 23
disease-free survival (22) 22
prognosis (22) 22
survival rate (22) 22
tumors (22) 22
metastases (21) 21
abdominal surgery (20) 20
antineoplastic combined chemotherapy protocols - adverse effects (20) 20
gastroenterology & hepatology (20) 20
oncology, experimental (19) 19
adenocarcinoma (18) 18
antimitotic agents (18) 18
antineoplastic agents (18) 18
capecitabine (18) 18
irinotecan (18) 18
drug combinations (17) 17
medical research (17) 17
s-1 (17) 17
stomach neoplasms - mortality (17) 17
antineoplastic agents - therapeutic use (16) 16
colorectal neoplasms - genetics (16) 16
fluorouracil - administration & dosage (16) 16
leucovorin (16) 16
original (16) 16
camptothecin - analogs & derivatives (15) 15
cisplatin - administration & dosage (15) 15
drug administration schedule (15) 15
drug therapy (15) 15
phase-iii (15) 15
5-fluorouracil (14) 14
cetuximab (14) 14
follow-up studies (14) 14
microsatellite instability (14) 14
paclitaxel (14) 14
studies (14) 14
1st-line therapy (13) 13
bevacizumab (13) 13
cancer patients (13) 13
colorectal carcinoma (13) 13
medical prognosis (13) 13
neutropenia (13) 13
open-label (13) 13
surgery (13) 13
combination (12) 12
retrospective studies (12) 12
safety (12) 12
antineoplastic combined chemotherapy protocols - administration & dosage (11) 11
development and progression (11) 11
epidermal growth factor (11) 11
genetic aspects (11) 11
immunohistochemistry (11) 11
kaplan-meier estimate (11) 11
kras (11) 11
oxonic acid - administration & dosage (11) 11
tegafur - administration & dosage (11) 11
toxicity (11) 11
1st-line treatment (10) 10
adjuvant chemotherapy (10) 10
advanced gastric cancer (10) 10
camptothecin - administration & dosage (10) 10
diarrhea (10) 10
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2009, Volume 10, Issue 11, pp. 1063 - 1069
Summary Background The best chemotherapy regimen for metastatic gastric cancer is uncertain, but promising findings have been reported with irinotecan plus... 
Hematology, Oncology and Palliative Medicine | SUPPORTIVE CARE | 5-FLUOROURACIL | ONCOLOGY | HIGH-DOSE METHOTREXATE | DOXORUBICIN | ADVANCED ESOPHAGOGASTRIC CANCER | COOPERATIVE GROUP | EUROPEAN-ORGANIZATION | 1ST-LINE THERAPY | III TRIAL | CHEMOTHERAPY | Japan - epidemiology | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Stomach Neoplasms - secondary | Cisplatin - administration & dosage | Young Adult | Fluorouracil - therapeutic use | Fluorouracil - adverse effects | Time Factors | Adult | Camptothecin - administration & dosage | Female | Camptothecin - analogs & derivatives | Drug Administration Schedule | Risk Assessment | Administration, Oral | Tegafur - adverse effects | Tegafur - therapeutic use | Proportional Hazards Models | Treatment Outcome | Stomach Neoplasms - drug therapy | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Oxonic Acid - adverse effects | Disease-Free Survival | Antimetabolites, Antineoplastic - therapeutic use | Oxonic Acid - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Antimetabolites, Antineoplastic - adverse effects | Aged | Infusions, Intravenous | Stomach Neoplasms - mortality | Drug Combinations | Adenocarcinoma - mortality | Chemotherapy | Oncology, Experimental | Information services | Research | Metastasis | Stomach cancer | Information services industry | Cancer | Fluorouracil | Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 5, pp. 631 - 639
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 9, pp. 853 - 860
Summary Background Fluorouracil and folinic acid with either oxaliplatin (FOLFOX) or irinotecan (FOLFIRI) are widely used as first-line or second-line... 
Hematology, Oncology and Palliative Medicine | TRIAL | CAPECITABINE | 1ST-LINE TREATMENT | INFUSIONAL FLUOROURACIL/LEUCOVORIN | THERAPY | ONCOLOGY | 5-FLUOROURACIL/FOLINIC ACID | FLUOROPYRIMIDINES | OXALIPLATIN | III NONINFERIORITY | FAILURE | Prodrugs - administration & dosage | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Colorectal Neoplasms - drug therapy | Adult | Camptothecin - administration & dosage | Female | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Camptothecin - adverse effects | Fluorouracil - analogs & derivatives | Tegafur - adverse effects | Kaplan-Meier Estimate | Oxonic Acid - administration & dosage | Adenocarcinoma - drug therapy | Oxonic Acid - adverse effects | Disease-Free Survival | Prodrugs - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Tegafur - administration & dosage | Aged | Drug Combinations | Adenocarcinoma - mortality | Medical colleges | Chemotherapy | Oncology, Experimental | Colorectal cancer | Leucovorin | Research | Metastasis | Cancer | Fluorouracil | Analysis
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 12/2013, Volume 31, Issue 35, pp. 4438 - 4444
Journal Article
Nihon Naika Gakkai Zasshi, ISSN 0021-5384, 2015, Volume 106, Issue Suppl, pp. 123 - 123b
Journal Article
Investigational New Drugs, ISSN 0167-6997, 8/2012, Volume 30, Issue 4, pp. 1621 - 1627
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 1, pp. 99 - 108
Journal Article
Gastric Cancer, ISSN 1436-3291, 10/2015, Volume 18, Issue 4, pp. 824 - 832
This multicenter, randomized phase II trial was conducted to compare the efficacy and safety of nimotuzumab plus irinotecan (N-IRI) versus irinotecan alone... 
Irinotecan | Anti-EGFR | Medicine & Public Health | Gastroenterology | Second-line therapy | Abdominal Surgery | Oncology | Cancer Research | Surgical Oncology | Advanced gastric cancer | Nimotuzumab | ADVANCED ESOPHAGOGASTRIC CANCER | MONOCLONAL-ANTIBODY H-R3 | CHEMOTHERAPY PLUS | CELL LUNG-CANCER | CAPECITABINE | GROWTH-FACTOR RECEPTOR | SUPPORTIVE CARE | CISPLATIN | ONCOLOGY | EGFR ANTIBODY | 1ST-LINE THERAPY | GASTROENTEROLOGY & HEPATOLOGY | Immunohistochemistry | Receptor, Epidermal Growth Factor - genetics | Humans | Middle Aged | Neoplasm Recurrence, Local - drug therapy | Male | Neoplasm Recurrence, Local - mortality | Antibodies, Monoclonal, Humanized - administration & dosage | DNA Mutational Analysis | Polymerase Chain Reaction | Adult | Camptothecin - administration & dosage | Female | Adenocarcinoma - genetics | Camptothecin - analogs & derivatives | Genes, ras - genetics | Stomach Neoplasms - genetics | Antibodies, Monoclonal, Humanized - adverse effects | Camptothecin - adverse effects | Receptor, Epidermal Growth Factor - biosynthesis | Receptor, ErbB-2 - biosynthesis | Kaplan-Meier Estimate | In Situ Hybridization, Fluorescence | Treatment Outcome | Stomach Neoplasms - drug therapy | Adenocarcinoma - drug therapy | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoplasm Recurrence, Local - genetics | Aged | Stomach Neoplasms - mortality | Salvage Therapy - methods | Adenocarcinoma - mortality | Antimitotic agents | Care and treatment | Cancer patients | Clinical trials | Product development | Antineoplastic agents | Stomach cancer | Cancer | Original
Journal Article
Journal Article
Journal Article